Sugi Predict

Sugi Predict / Compounds / SCHEMBL377481

SCHEMBL377481

SCHEMBL377481

CNC1CCN(c2ccc(-c3nc4cc(OC)cc(OC)c4c(=O)[nH]3)cc2)C1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 9/20 0.51
▸ HDAC4 P56524 9/20 0.51
▸ HDAC1 Q13547 9/20 0.51
▸ HDAC7 Q8WUI4 9/20 0.51
▸ HDAC2 Q92769 9/20 0.51
▸ HDAC10 Q969S8 9/20 0.51
▸ HDAC11 Q96DB2 9/20 0.51
▸ HDAC8 Q9BY41 9/20 0.51
▸ HDAC6 Q9UBN7 9/20 0.51
▸ HDAC9 Q9UKV0 9/20 0.51
▸ HDAC5 Q9UQL6 9/20 0.51
▸ BRD4 O60885 9/20 0.50
▸ BRD2 P25440 2/20 0.48
▸ CSNK1A1 P48729 1/20 0.48
▸ CSNK1D P48730 1/20 0.48
▸ CSNK1E P49674 1/20 0.48
▸ CSNK1G2 P78368 1/20 0.48
▸ BRD3 Q15059 1/20 0.48
▸ CSNK1G1 Q9HCP0 1/20 0.48
▸ IL17A Q16552 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31115582 1.00 HDAC3 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL25233612 0.94 BRD4 (0.54) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL377594 0.90 HDAC1 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL377961 0.89 HDAC3 (0.49) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL377988 0.87 BRD4 (0.52) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL378114 0.86 BRD4 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL377799 0.86 BRD4 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL377732 0.86 BRD4 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL378287 0.85 BRD4 (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL23082253 0.85 BRD4 (0.51) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 — — EP claimed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 — — US claimed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 — — US claimed
WO-2013175281-A1 USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS RVX THERAPEUTICS INC. (CA) 2013-11-28 — — WO claimed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US claimed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 — — EP claimed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 — — WO claimed
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 — — EP disclosed
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 — — US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 — — US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 — — US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 — — US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 — — US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 — — US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 — — US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 — — US disclosed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 — — EP disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 — — WO disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 HDAC3 1263/4885HDAC4 981/4885HDAC1 576/4885
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 HDAC3 1275/4885HDAC4 910/4885HDAC1 582/4885
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 HDAC3 54/4885HDAC4 84/4885HDAC1 30/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 HDAC3 1263/4885HDAC4 981/4885HDAC1 576/4885
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 HDAC3 1263/4885HDAC4 981/4885HDAC1 576/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 HDAC3 1263/4885HDAC4 981/4885HDAC1 576/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 HDAC3 1275/4885HDAC4 910/4885HDAC1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.